Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $401,738.15 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 66,403 shares of the business’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $6.05, for a total transaction of $401,738.15. Following the completion of the sale, the insider directly owned 14,598,536 shares of the company’s stock, valued at $88,321,142.80. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total transaction of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total transaction of $158,944.50.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total transaction of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total transaction of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total transaction of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total transaction of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total transaction of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total transaction of $13,984.00.

Vir Biotechnology Trading Up 0.3%

Shares of NASDAQ:VIR opened at $5.93 on Friday. The company has a 50-day moving average price of $5.46 and a 200-day moving average price of $5.31. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45. The company has a market cap of $823.80 million, a price-to-earnings ratio of -1.48 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. During the same period in the previous year, the business earned ($1.02) EPS. The business’s revenue was down 60.5% compared to the same quarter last year. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a report on Monday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Tuesday, October 14th. Evercore ISI assumed coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, Raymond James Financial assumed coverage on shares of Vir Biotechnology in a report on Friday, July 11th. They issued an “outperform” rating for the company. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.30.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the second quarter valued at approximately $35,000. GAMMA Investing LLC increased its stake in shares of Vir Biotechnology by 524.3% during the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after purchasing an additional 5,972 shares in the last quarter. Apollon Wealth Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth about $50,000. PNC Financial Services Group Inc. raised its position in shares of Vir Biotechnology by 26.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after purchasing an additional 2,171 shares during the last quarter. Finally, FORA Capital LLC purchased a new position in shares of Vir Biotechnology in the 1st quarter worth about $70,000. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).